Parallel Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Parallel Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-14,000	Closed	-$72K	–	2581
2019 Q2	$72K	Buy	14,000 +5,000	+56%	+$22.5K	0.01%	774
2019 Q1	$32K	Hold	9,000	–	–	﹤0.01%	1039
2018 Q4	$55K	Hold	9,000	–	–	0.01%	728
2018 Q3	$53K	Hold	9,000	–	–	0.01%	799
2018 Q2	$38K	Hold	9,000	–	–	0.01%	832
2018 Q1	$40K	Hold	9,000	–	–	0.01%	780
2017 Q4	$47K	Hold	9,000	–	–	0.01%	724
2017 Q3	$63K	Buy	9,000 +5,000	+125%	+$31.6K	0.01%	612
2017 Q2	$27K	Buy	4,000 +2,000	+100%	+$12.3K	0.01%	898
2017 Q1	$12K	Hold	2,000	–	–	﹤0.01%	1167
2016 Q4	$14K	Buy	+2,000	New	+$16.2K	﹤0.01%	1010

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Parallel Advisors's PETX Position: Q3 2019 in Review

Parallel Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 14,000 shares — an estimated $72K sold.

Parallel Advisors first reported a position in PETX in Q4 2016 and held it in 11 quarters. The position peaked at $72K in Q2 2019. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Parallel Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Parallel Advisors sold 14,000 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $72K.
Parallel Advisors first reported a position in Aratana Therapeutics, Inc. in Q4 2016 and held it in 11 quarters.
Parallel Advisors's Aratana Therapeutics, Inc. position peaked at $72K in Q2 2019.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Parallel Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.